ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $1,843,000 | +3.0% | 11,940 | -1.4% | 0.00% | 0.0% |
Q2 2020 | $1,790,000 | -9.8% | 12,105 | -31.3% | 0.00% | 0.0% |
Q1 2020 | $1,985,000 | -13.7% | 17,628 | +6.6% | 0.00% | 0.0% |
Q4 2019 | $2,300,000 | +83.4% | 16,536 | +27.0% | 0.00% | 0.0% |
Q3 2019 | $1,254,000 | -9.4% | 13,020 | +8.4% | 0.00% | 0.0% |
Q2 2019 | $1,384,000 | +240.9% | 12,015 | +248.6% | 0.00% | -50.0% |
Q1 2019 | $406,000 | – | 3,447 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |